VANCOUVER, British Columbia / May 28, 2024 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time).
A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.
| Last Trade: | US$5.91 |
| Daily Change: | -0.26 -4.21 |
| Daily Volume: | 5,491,457 |
| Market Cap: | US$1.770B |
August 07, 2025 May 30, 2025 May 12, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
